Pharmaceuticals
News Category
VERAXA Biotech's Antibody Platform Positions It for Strategic Partnerships Amid Strong Sector Deal Activity
The article highlights that VERAXA Biotech AG's technology platform in antibody-drug conjugates and T-cell engagers places it favorably for potential ...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating production to improve efficiency and profitability, affecting 32 employees.
Ace Therapeutics Launches Comprehensive Preclinical Pain Research Platform to Accelerate Analgesic Drug Development
Ace Therapeutics announces full-spectrum preclinical analgesic drug development services with validated in vivo pain models and integrated research ca...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Annovis Bio Raises $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Therapies
Annovis Bio announced a $3.4 million registered direct offering led by H.C. Wainwright, with proceeds for working capital, signaling continued investo...
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution Agreement with Phalanx for Mexican Market Expansion
Voyageur Pharmaceuticals has signed a non-exclusive distribution and wholesale agreement with Phalanx to register and distribute its barium contrast m...
ABVC BioPharma Receives Additional $100,000 Licensing Payment from OncoX, Totaling $695,950
ABVC BioPharma's oncology partner OncoX made a fifth licensing payment in 2025, demonstrating cash flow visibility and advancing ABVC's licensing-driv...
Medios AG Appoints Thomas Meier as New CEO to Drive Growth
Medios AG has appointed Thomas Meier, former CEO of Bachem Holding AG, as its new CEO starting February 2026, signaling a strategic move to accelerate...
Soligenix Announces Q3 2025 Financial Results and Clinical Milestones for Psoriasis and CTCL Programs
Soligenix reported Q3 2025 financials, highlighting upcoming Phase 2a results for SGX302 in psoriasis and progress in its Phase 3 HyBryte study for CT...
Voyageur Pharmaceuticals Appoints Virginia Alling to Board, Bolstering U.S. Market Expansion
Voyageur Pharmaceuticals strengthens its board with seasoned financial executive Virginia Alling to accelerate U.S. capital market access and support ...
Redcare Pharmacy Appoints Hendrik Krampe as New CFO
Redcare Pharmacy's Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective December 1, 2025, to lead the company's finan...
NanoViricides Raises $6 Million in Registered Direct Offering to Fund Antiviral Drug Development
NanoViricides announced a $6 million registered direct offering with warrants to support working capital and general corporate purposes as it advances...
TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer to Advance Oncology Pipeline
TransCode Therapeutics appointed Dr. Michel Janicot as Senior Development Officer, bringing over 35 years of oncology drug-development experience to g...
CTT Pharma CEO to Issue Shareholder Letter with Updates on S-1 Filing, Manufacturing, and Scientific Manuscript
CTT Pharmaceutical Holdings' CEO will release a shareholder letter on December 2, 2025, detailing key initiatives including S-1 filing progress, manuf...
Creative Bioarray Launches In Vitro Metabolism Assay Kits to Accelerate Drug Development
Creative Bioarray announced new in vitro metabolism assay kits that leverage CYP450 and UGT enzyme systems to enhance drug testing precision and effic...
South Fork Instruments Launches Kemtrak UV Spectra for Real-Time Deep-UV Measurement in Bioprocessing
South Fork Instruments introduces the Kemtrak UV Spectra Process Analyzer, a multi-wavelength deep-UV photometer for real-time monitoring of biomolecu...
Antisense Oligonucleotides Gain Regulatory Momentum, Promising to Transform Drug Development Economics
With six new FDA approvals in 2023–2024 and over 50 candidates in trials, antisense oligonucleotides (ASOs) are shifting drug development odds through...
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
Telomir Pharmaceuticals announced positive safety results from IND-enabling studies for Telomir-1, supporting its advancement toward first-in-human cl...
Tonix Pharmaceuticals Advances TNX-4800 Lyme Disease Prophylaxis Program Toward FDA Meeting
Tonix Pharmaceuticals provides an update on its TNX-4800 program for seasonal Lyme disease prophylaxis, planning an FDA meeting in 2026 and GMP manufa...
Voyageur Pharmaceuticals Secures Exclusive Iodine Extraction Technology and Appoints Dr. Brian Mueller as Director of Chemistry
Voyageur Pharmaceuticals acquires exclusive rights to a proprietary iodine extraction technology and appoints its inventor, Dr. Brian Mueller, as Dire...
LIXTE Biotechnology Engages IBN to Enhance Corporate Communications
LIXTE Biotechnology Holdings (NASDAQ: LIXT) has hired IBN to expand its corporate communications reach, aiming to increase awareness of its lead cance...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Contrast Drug Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Lixte Biotechnology to Present at DealFlow Discovery Conference, Highlighting Progress of Lead Cancer Drug LB-100
Lixte Biotechnology Holdings announced its participation in the DealFlow Discovery Conference, where CEO Geordan Pursglove will meet with investors as...
Protheragen Expands Drug Analysis Services with Integrated Stability, Impurity, and Chemical-Physical Testing
Protheragen announces integrated drug analysis solutions combining stability studies, impurity testing, and chemical-physical tests to support pharmac...
Creative Biolabs Upgrades Biosimilar Development and CDMO Platform for Enhanced Physicochemical and Biological Characterization
Creative Biolabs announces strategic upgrades to its biosimilar development and CDMO platform, offering comprehensive physicochemical and biological a...
Quantumzyme Corp. Outlines 2025 Progress and 2026 Strategic Priorities, Including AI Focus and Name Change
Quantumzyme Corp. details its 2025 achievements in enzyme R&D and AI integration, and announces plans for a name change to Quantum Genesis AI Corp. as...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut-S in Metastatic Bladder Cancer, Expanding Potential Beyond Ovarian Cancer
BioVaxys announced positive Phase 2 results for maveropepimut-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladder cancer...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition, Underscoring Strong Cash Flow
Knight Therapeutics (TSX: GUD) has fully repaid the $60 million drawn from its revolving credit facility in June 2025 to finance the acquisition of Pa...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that Phase 2a trial results for SPL026, published in Nature Medicine, showed significant reduction in depressive symptoms in ma...
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Oncotelic Therapeutics is highlighted in a BioMedWire editorial as its late-stage oncology and CNS programs align with the growing trend in biotech M&...
NETHERTON NOW Campaign Surpasses 2 Million Views, Raising Global Awareness for Rare Disease Day
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has achieved 2 million video views and 24 million impressions, highlighting the urgent need fo...
Soligenix Receives Positive EMA Opinion for Orphan Drug Designation of Dusquetide in Behçet's Disease
Soligenix announced that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion for orphan drug designation...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects, Targeting 2027 U.S. Market Entry
Voyageur provides a corporate update on its vertically integrated barium and iodine contrast media projects, including progress on bankable feasibilit...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating sites in Oklahoma and Texas for a vertically integrated contrast media facility that could reduce costs and sec...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board of Directors, bringing extensive pharmaceutical industry experience and expertis...
LIXTE Biotechnology’s LB-100: The World’s Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology’s LB-100, the only clinical-stage PP2A inhibitor, shows promise in enhancing cancer therapy by sensitizing tumors to immunotherapy...
LIXTE Biotechnology Files 2025 Form 10-K, Highlights Transformational Year with Clinical Progress and Strategic Expansion
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing a year of leadership changes, clinical advancement of its lead compoun...
PolyPeptide Shareholders Approve All Proposals at 2026 Annual General Meeting
PolyPeptide Group AG shareholders approved all board proposals, including re-election of directors and auditors, at the company's fifth annual general...
Soligenix Leverages Platform Technology to Streamline Drug Development for Multiple Indications
Soligenix Inc. uses its synthetic hypericin platform to target cutaneous T-cell lymphoma and psoriasis, demonstrating how platform-based drug developm...
LIXTE Biotechnology Positions LB-100 as Novel Approach in Cancer Treatment Landscape
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor, in multiple clinical trials for solid tumors with high unmet medica...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, providing a real-time molecular intelligence engine...
Earth Science Tech Inc. (ETST) Positions Itself at the Intersection of Telemedicine, Pharmacy, and Healthcare Services
Earth Science Tech Inc. (ETST) has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emph...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May 2026
Tonix Pharmaceuticals announced its participation in two May investor conferences, highlighting its commercial-stage CNS and immunology pipeline, incl...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox and Other Viral Diseases
NanoViricides updates progress on broad-spectrum antiviral NV-387, with regulatory approval for Phase II MPox trial in DRC and FDA orphan drug designa...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Precision Oncology
Lantern Pharma closed a $4.4 million registered direct offering, with potential for an additional $4.85 million from warrants, to fund its AI-powered ...
NanoViricides Prices $2 Million Registered Direct Offering to Fund Clinical Development
NanoViricides has agreed to sell shares and warrants to an institutional investor for gross proceeds of $2 million, with funds likely supporting its l...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Drug Discovery
Sino Biological's new XPressMAX™ kit enables ultra-fast, high-throughput protein synthesis in 3 hours, integrating with AI-driven screening to speed a...
Carmed Pharmaceuticals Gains CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is expanding into the U.S. market, highlighted by ...